This article describes the use of poorly absorbed antibiotics for the treatment of traveler's diarrhea. Poorly absorbed oral antibiotics can deliver high concentrations of drug to the site of enteric infection with minimal risk of systemic adverse effects, toxicity, and drug interactions. Compared with systemically absorbed oral antibiotics, poorly absorbed oral antibiotics may be less associated with the pressure that leads to the development of bacterial resistance, because they do not affect bacteria outside the gastrointestinal tract. In clinical studies, poorly absorbed oral antibiotics, including aztreonam, bicozamycin, and rifaximin, were more effective than and as well tolerated as placebo; in particular, rifaximin was as effective as oral ciprofloxacin in reducing the duration of illness in traveler's diarrhea. More research is warranted to delineate the effects of poorly absorbed antibiotics in invasive infection and to assess the potential for the development of bacterial resistance.
Given the high likelihood that traveler's diarrhea has a bacterial cause, Infectious Diseases Society of America guidelines recommend empirical antibiotic therapy for its treatment [1] , and persons traveling from developed to developing countries have been advised to carry antibiotics for self-treatment [2, 3] . Antibiotics can eradicate bacterial infection, thus providing symptomatic relief, reducing the duration of illness, decreasing the risk of disease transmission, and possibly preventing long-term infectious complications [4] . The important role of antibiotics in the treatment of traveler's diarrhea notwithstanding, many of the current antibiotics used to treat traveler's diarrhea are associated with limitations that have stimulated a search for improved antibacterial options. In comparative trials, poorly absorbed oral antibiotics are as effective as systemically absorbed oral antibiotics for the treatment and prevention of traveler's diarrhea [3, [5] [6] [7] [8] . Because the poorly absorbed (!0.4% absorption) oral antibiotic rif-is warranted. However, because the illness is self-limited and because treatment must be self-administered, it is important that treatment is both safe and easy to use.
The safety profiles of absorbable antibiotics can limit their usefulness for traveler's diarrhea [4, 6] . For example, fluoroquinolones are not recommended for children and are more likely to be associated with adverse effects in elderly persons. Systemic antibiotics are usually difficult to use during pregnancy. Ideally, an antibiotic used for the treatment of traveler's diarrhea should be associated with a minimal risk of adverse events of any severity or duration.
The usefulness of systemic oral antibiotics in treating traveler's diarrhea can be compromised by bacterial resistance [15] [16] [17] [18] [19] [20] . Systemically absorbed antibiotics are typically used on a widespread basis, and antimicrobial resistance eventually follows within 10 years of their widespread use. Bacterial resistance has rendered past standards of treatment with antibiotics, including penicillins, tetracyclines, trimethoprim-sulfamethoxazole, and most macrolides, obsolete for traveler's diarrhea and is eroding the usefulness of the current mainstays of antidiarrheal therapy-the quinolones and azithromycin [15] [16] [17] [18] [19] [20] [21] [22] [23] . In Thailand, for example, the incidence of Campylobacter resistance to ciprofloxacin doubled, from 40% to 180%, between 1993 and 1995 [19] . Among Campylobacter species, resistance is also emerging to the azalide azithromycin, which heretofore has been regarded as an important antidiarrheal treatment option because of its efficacy against multidrug-resistant Campylobacter species [19, 20] .
Increasing bacterial resistance can result in the loss of the clinical efficacy of mainstay antibiotics used to treat bacterial diarrhea, a point underlined by a recent report indicating that diarrhea caused by ciprofloxacin-resistant Campylobacter species was of longer duration than diarrhea caused by ciprofloxacin-susceptible Campylobacter species [23] . Moreover, bacterial resistance engendered by the use of antibiotics to treat traveler's diarrhea could also reduce the efficacy of antibiotics for the treatment of nondiarrheal bacterial illnesses. Results of a surveillance study show that the increased use of ciprofloxacin in the United States from 1994 to 2000 coincided with a reduction, from 86% to 76%, in the overall susceptibility to ciprofloxacin among gram-negative aerobic organisms recovered from patients in intensive care units [24] . It would be optimal if systemically absorbed antibiotics could be reserved for the serious infections for which they are indicated (e.g., fluoroquinolones for serious infections caused by gram-negative aerobic bacteria and azithromycin for serious respiratory tract infections), and if their use for less-serious enteric infections could be avoided or minimized. Nevertheless, both drugs are likely to be used as long as they are clinically effective. It is unlikely that use will decrease until concerns of increasing bacterial resistance become a reality.
CLINICAL STUDIES OF POORLY ABSORBED ANTIBIOTICS USED FOR TRAVELER'S DIARRHEA
Poorly absorbed oral antibiotics differ in clinically important ways from systemically absorbed oral antibiotics. Because systemic exposure is minimized, poorly absorbed antibiotics are associated with a low risk of adverse effects, toxicity, and drug interactions. In addition, unlike systemically absorbed oral antibiotics, poorly absorbed antibiotics specifically targeting the gut do not exert antimicrobial pressure on bacterial flora outside the gut.
Several poorly absorbed antibiotics, including aztreonam, bicozamycin, nifuroxazide, and rifaximin, have been studied in controlled studies of people with traveler's diarrhea [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] (author's unpublished data). Bicozamycin and rifaximin have been evaluated both as acute treatment and as prophylaxis for traveler's diarrhea [25-29, 31, 32 ] (author's unpublished data). The aminoglycoside neomycin was studied as a prophylactic agent for traveler's diarrhea and for US children with shigellosis [35, 36] .
Aminoglycosides, such as neomycin, are generally not absorbed well when given orally. Kean et al. [36] were among the first researchers to recognize the potential value of using poorly absorbed antibiotics in the treatment of traveler's diarrhea. In a study of US students in Mexico in 1960, Kean et al. [36] demonstrated that treatment with 1 g of neomycin given daily for 14 days was associated with a reduced incidence of traveler's diarrhea (5.1%), compared with the incidence noted for placebo-treated patients (17.3%) (table 1). When that study was conducted, the etiology of traveler's diarrhea was not known, but Kean et al. [36] suggested a bacterial etiology. In another study [35] , neomycin was compared with ampicillin for the treatment of shigellosis in US children. Ampicillin was clearly superior to neomycin (table 1), a finding that suggests that neomycin is not effective for such intercellular organisms as Shigella species.
Another poorly absorbed antibiotic used in Europe is the nitrofuran derivative nifuroxazide (Ercefuryl; Sanofi-Aventis). This antibiotic is available over the counter in France. It has been used both as diarrheal treatment and prophylaxis. Its efficacy appears to be less than that of loperamide, but the drug appeared to be useful as a prophylactic agent among race car drivers in Morocco [33, 34] .
Poorly absorbed antibiotics for the treatment of traveler's diarrhea. Bicyclomycin (bicozamycin) is the first nonaminoglycoside poorly absorbed (!3% absorption) antibiotic to be evaluated for the treatment of traveler's diarrhea. This antibiotic interferes with the cell wall synthesis. In a randomized, doubleblind study of 138 adults who acquired traveler's diarrhea while visiting Guadalajara, Mexico, bicozamycin (500 mg given 4 times daily;
) was compared with placebo ( ) for 3 days n p 74 n p 74 and was found to be effective in reducing the duration of illness Figure 1 . Duration of diarrhea, expressed in hours, attributed to shigellosis, enterotoxigenic Escherichia coli (ETEC), and all causes in a placebocontrolled study of bicozamycin [25] . * , bicozamycin vs. placebo. in persons infected with enterotoxigenic E. coli, Shigella species, and other pathogens (figure 1) [25] . Bicozamycin therapy also shortened the excretion time of Shigella species, compared with that for placebo. The results of that study contradicted the idea that poorly absorbed antibiotics could not be used to treat Shigella species, which is an enteroinvasive pathogen. In a subsequent study, bicozamycin was also effective in preventing traveler's diarrhea [31] . In the prophylaxis study, bicozamycin reduced the aerobic, gram-negative, normal colonic bacterial flora, an effect that was reversible after the drug was discontinued. Unfortunately, this antibiotic was not developed for clinical use. A similar pattern of results was later obtained with the use of aztreonam (table 1), !1% of which is absorbed after oral administration [30] . In a randomized, double-blind study of patients who acquired traveler's diarrhea during travel from the United States to Mexico ( ), treatment with 100 mg n p 99 of aztreonam given 3 times daily for 3 days shortened the duration of illness of any cause by 40 h and shortened the duration of illness attributed to enterotoxigenic E. coli by 50 h, compared with placebo ( ) [30] . The overall incidence of n p 93 adverse events did not differ between the aztreonam group and the placebo group. Despite the promising results of these studies, none of these agents was developed commercially for the treatment of traveler's diarrhea.
Of the poorly absorbed antibiotics, rifaximin has been most thoroughly evaluated for the treatment of traveler's diarrhea. Rifaximin was first marketed in Italy in 1987 and is now used in 17 countries for the treatment of bacterial illnesses, including infectious diarrhea, Clostridium difficile-associated colitis, small intestinal bacterial overgrowth, and hepatic encephalopathy. It is also used in some countries for pre-and postsurgical prophylaxis of gastrointestinal infections and has been studied as treatment for diverticular disease, Crohn disease, and pouchitis (i.e., acute inflammation of the mucosa of an ileal reservoir or pouch that has been surgically created after procedures such as total colectomy for inflammatory bowel disease or multiple polyposis).
Four randomized, double-blind, placebo-or comparatorcontrolled, parallel-group clinical trials were conducted among adults who contracted traveler's diarrhea during travel to Guatemala, Mexico, Kenya, India, or Jamaica [26] [27] [28] (author's unpublished data). Traveler's diarrhea was defined as at least 3 unformed stools within the 24 h preceding randomization and at least 1 sign or symptom of enteric infection (i.e., abdominal pain or cramps, nausea, vomiting, fever [i.e., temperature of at least 100ЊF or 37.8ЊC], mild dysentery, fecal urgency, excessive gas/flatulence, or tenesmus). In Study 1, patients were treated [26] . In Study 2, patients were treated for 3 days with 400 mg of rifaximin 2 times daily ( ) or 500 mg of n p 93 ciprofloxacin 2 times daily ( ) [27] . In Study 3, patients n p 94 were treated for 5 days with 200 mg of rifaximin 3 times daily ( ), 400 mg of rifaximin 3 times daily ( ),
have not yet been published; therefore, the study is described only briefly here. The primary efficacy end point for the studies was the median time to the last unformed (i.e., watery or soft) stool (TLUS), which is defined as the interval beginning when the first dose of study medication was administered and ending when the last unformed stool was passed.
Overall, the results show that rifaximin was significantly better than placebo and was comparable to ciprofloxacin or trimethoprim-sulfamethoxazole in conferring clinical improvement of traveler's diarrhea (table 2 and figure 2) [26-28] (author's unpublished data). In Study 1, rifaximin approximately halved the TLUS relative to that observed with placebo (33 h for each rifaximin dose vs. 60 h for placebo) and conferred comparable improvement in other efficacy measures (table 2) [26] . That study also demonstrated that rifaximin was particularly effective in shortening the duration of illness among the subgroup of patients infected with enteroaggregative E. coli, which is a very common cause of traveler's diarrhea [29] . In Study 2, rifaximin was as effective as ciprofloxacin in reducing TLUS and improving other clinical end points (table 2) [27] . In Study 3, which was a smaller clinical trial, rifaximin was comparable to trimethoprim-sulfamethoxazole with regard to the median TLUS and the other measurements of efficacy (table 2) [28] .
In Study 4, which is not summarized in table 2, rifaximin and ciprofloxacin significantly reduced TLUS, compared with placebo (author's unpublished data). Rifaximin and ciprofloxacin appeared to be comparably effective in reducing TLUS in the sample as a whole (32 h for rifaximin, 29 h for ciprofloxacin, and 66 h for placebo). In that study, rifaximin was most effective for the subgroups of patients infected with diarrheagenic E. coli and for patients for whom no pathogen was identified. Rifaximin was not effective in that study for the treatment of diarrhea due to inflammatory pathogens, including Shigella, Salmonella, and Campylobacter species.
The safety and tolerability profiles of rifaximin were assessed in these 4 studies, which involved 597 patients randomized to receive у600 mg of rifaximin daily and 443 patients randomized to receive placebo (Studies 1 and 4), ciprofloxacin (Studies 2 and 4), or trimethoprim-sulfamethoxazole (Study 3). Investigators were asked to report any untoward medical occurrence as an adverse event, regardless of whether they considered it to be caused by study medication. The adverse-event profile of rifaximin was comparable to that of placebo in the 2 studies that included a placebo control group (table 3) [26] (author's unpublished data). The most common adverse events, including flatulence and abdominal pain, probably constituted symptoms of infectious diarrhea itself, rather than adverse effects of study medication. In the active comparator studies, as in the placebo-controlled studies, diarrheal symptoms were the most common adverse events across treatment groups. The incidence of any adverse event associated with the use of rifaximin was the same or less than that associated with the use of other active comparators.
Poorly absorbed antibiotics for the prevention of traveler's diarrhea. Chemoprophylaxis of traveler's diarrhea has generally been discouraged because of the risk of adverse effects, concerns about promoting antibiotic resistance, the lack of alternative treatments if diarrhea occurred, and the rapid efficacy observed in association with treatment regimens [5, 7] . There are, however, situations in which preventing or decreasing the risk of traveler's diarrhea can be indicated. For example, traveler's diarrhea should be prevented among patients with underlying illnesses that would make a severe bout of diarrhea life threatening and among patients who cannot afford to become sick and are willing to take precautions to avoid diarrhea. Chemoprophylaxis is also the only way to avoid postinfectious diarrheal complications, such as irritable bowel syndrome. Rifaximin is the first agent that might be considered for chemoprophylaxis, because it does not appear to alter the normal intestinal bacterial flora significantly (see below), and because it has an excellent safety and tolerability profile.
As discussed by H. L. DuPont elsewhere in this supplement [37] , rifaximin has been evaluated in the prevention of traveler's diarrhea. In a double-blind, placebo-controlled study in which US adults ( ) were randomized, within 72 h of their n p 209 arrival in Mexico, to receive rifaximin or placebo for 2 weeks, rifaximin significantly protected against the occurrence of diarrhea during a 3-week observation period, compared with placebo [32] . The incidence of adverse events did not differ between patients treated with rifaximin and those treated with placebo.
UNANSWERED QUESTIONS ABOUT THE USE OF POORLY ABSORBED ORAL ANTIBIOTICS FOR TRAVELER'S DIARRHEA
The clinical data on poorly absorbed antibiotics support their benefits in the treatment and prevention of traveler's diarrhea. Furthermore, poorly absorbed antibiotics are well tolerated, [35] , whereas bicozamycin and aztreonam have been shown to be effective in the presence of signs of mild invasive enteric infection (e.g., fecal leukocyte-positive diarrheal stools, shigellosis, and bloody stools) [25, 30] . Why bicozamycin was effective but neomycin was not is not clear, but it may be the result of better penetration by bicozamycin into the intestinal epithelial cell or a difference in disease severity between shigellosis associated with traveler's diarrhea and shigellosis that affects children. Although rifaximin has been shown to shorten the time to fecal excretion of Shigella species, it has not been shown to significantly shorten the duration of illness. Preliminary data from a challenge study of Shigella species demonstrated that rifaximin treatment was effective for mild illness but not for more moderate or severe illness (author's unpublished data). These data suggest that Shigella species sequestered in the intraepithelial space were no longer susceptible to rifaximin. This hypothesis was proven to be correct when it was demonstrated in a subsequent challenge study that pretreatment with rifaximin could completely prevent illness. Because Shigella species do not become invasive until they reach the large intestine, they are fully exposed to high intraluminal concentrations of rifaximin in the small intestine, with sufficient contact time to eradicate the organisms.
Whether rifaximin prophylaxis will be equally effective in preventing infections with other invasive organisms, such as Salmonella and Campylobacter species, remains to be proven. A second unanswered question concerns the extent to which clinically relevant bacterial resistance to poorly absorbed antibiotics could develop. That no clinically relevant resistance to rifaximin has emerged during 117 years of use of 1500 million tablets for enteric infections is consistent with the speculation that the circumscribed use of poorly absorbed antibiotics (for enteric infections only) reduces the risk of observing clinically relevant resistance. Rifaximin appears not to induce resistance in enteric flora. The development of rifaximin-and rifampinresistant intestinal coliforms was studied by plating stool samples from 27 subjects receiving rifaximin onto media containing rifaximin or rifampin before treatment (day 0), after a 3-day course of rifaximin (day 3), and after an additional 2 days (day 5) [38] . The susceptibility of enterococci grown on day 0 and day 3 was also studied in 71 subjects. Significant increases in antimicrobial-resistant coliform flora were not observed in stool samples obtained from either rifaximin-treated subjects or placebo-treated subjects, and enterococci showed similar susceptibilities both before and after a course of rifaximin treatment. Additional research is needed to delineate the effects of rifaximin on enteric flora and pathogens and to determine whether rifaximin differs from other antibiotics with respect to their potential for inducing clinically relevant resistance.
CONCLUSIONS
Poorly absorbed oral antibiotics clearly play an important role in the treatment of traveler's diarrhea. They can deliver high concentrations of antibiotic to the source of infection and are associated with a minimal risk of systemic adverse effects and toxicity. In addition, poorly absorbed oral antibiotics may be less associated with the pressure that leads to the development of bacterial resistance by virtue of their more circumscribed use. In clinical studies, aztreonam, bicozamycin, and rifaximin were more effective than placebo. Rifaximin was comparable to absorbable oral antibiotics in reducing the duration of illness in traveler's diarrhea. Furthermore, poorly absorbed antibiotics appear to have a tolerability profile comparable to that of placebo. In addition to advancing the treatment of traveler's diarrhea, the use of poorly absorbed antibiotics may pave the way for greater feasibility and acceptance of chemoprophylaxis of traveler's diarrhea. Now that rifaximin has been licensed in the United States and as its use increases, it will be important to monitor for increasing antimicrobial resistance.
